Tanner's Fight for Eczema Relief

0:00It's April 21st. Welcome in. This is Sydney News Today, where local news meets AI. I'm Corey with the story. 10-year-old Tanner Hosey from Narendara battled severe exema since he was six months old, scratching non-stop and ending up bloody and scarred. Nothing worked, no creams, no bass, until his doctor prescribed Dupre Lumab two years ago. Those injections cleared his skin fast, letting him play footy, ride bikes, and live like other kids. But here's the catch. For kids under 12 years old, Dupre Lumab isn't covered by the pharmaceutical benefit scheme, hitting families with bills up to $1,600 a month. Over 12 is just $25. Tanner started at 8 and his single mom scraped by on company 8, but that funding gets reviewed every six months, keeping them on edge. Mum Casey Ray says, watching Tanner suffer stole his childhood, with hospital trips and raw skin after playtime. Pediatric dermatologist Lee Twain Wang agrees, untreated severe

1:04exema leads to asthma, allergies, anxiety, even ADHD later on. Early treatment like this drug can change that trajectory for good. Back in March 2022, the pharmaceutical benefits advisory committee recommended it for under 12s, but the pharma company didn't follow. Up. Now Sinophys submitting fresh info for a July advisory meeting to reassess. Exema hits about 2.8 million Aussies, and groups like Exema Support Australia are pushing hard with their save our skin campaign. Families shouldn't choose between relief and ruin, hoping that July vote brings fair access for little ones like Tanner.